1. Home
  2. EIX vs INSM Comparison

EIX vs INSM Comparison

Compare EIX & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Edison International

EIX

Edison International

HOLD

Current Price

$71.32

Market Cap

27.8B

Sector

Utilities

ML Signal

HOLD

Logo Insmed Incorporated

INSM

Insmed Incorporated

N/A

Current Price

$123.69

Market Cap

22.4B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
EIX
INSM
Founded
1886
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Electric Utilities: Central
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
27.8B
22.4B
IPO Year
1994
2000

Fundamental Metrics

Financial Performance
Metric
EIX
INSM
Price
$71.32
$123.69
Analyst Decision
Hold
Strong Buy
Analyst Count
13
24
Target Price
$72.09
$201.17
AVG Volume (30 Days)
3.0M
3.1M
Earning Date
04-28-2026
05-07-2026
Dividend Yield
5.17%
N/A
EPS Growth
248.94
N/A
EPS
1.37
N/A
Revenue
$19,317,000,000.00
N/A
Revenue This Year
N/A
$182.31
Revenue Next Year
$3.17
$65.19
P/E Ratio
$51.59
N/A
Revenue Growth
9.76
N/A
52 Week Low
$52.00
$90.39
52 Week High
$81.62
$212.75

Technical Indicators

Market Signals
Indicator
EIX
INSM
Relative Strength Index (RSI) 44.26 59.38
Support Level $67.48 $95.24
Resistance Level $72.89 $140.30
Average True Range (ATR) 2.26 4.84
MACD -0.44 2.19
Stochastic Oscillator 30.32 65.82

Price Performance

Historical Comparison
EIX
INSM

About EIX Edison International

Edison International is the parent company of Southern California Edison, an electric utility that distributes electricity to 5 million customers in a 50,000-square-mile area of Southern California, excluding Los Angeles. Edison Energy owns interests in nonutility businesses that deal in energy-related products and services. In 2014, Edison International sold its wholesale power generation subsidiary Edison Mission Energy out of bankruptcy to NRG Energy.

About INSM Insmed Incorporated

Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.

Share on Social Networks: